Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment

Gene Therapy

Volumn 20, Issue 3, 2013, Pages 338-347

  Sugiyama, T ^a   Yoneda, M ^a   Kuraishi, T ^a   Hattori, S ^a   Inoue, Y ^b   Sato, H ^a   Kai, C ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; ONCOLYTIC VIRUS; RECOMBINANT MEASLES VIRUS SIGNALING LYMPHOCYTE ACTIVATION MOLECULE BLIND; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; HUMAN; HUMAN CELL; IN VIVO STUDY; MEASLES VIRUS; MOUSE; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS STRAIN;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HEK293 CELLS; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; MCF-7 CELLS; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTORS, CELL SURFACE; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS; MUS; POLIOVIRUS;

EID: 84874765309     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.44     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011; 22: 1000-1010.
3. Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, De Kruijf M et al. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011; 37: 618-632.
4. Griffin DE. Measles virus. In: David M, Knipe P, Peter M, Howley M, Griffin DE, Lamb RA, Malcolm A, Martin M, Bernard Roizman S, Stephen E, Straus M (eds). Fields Virology. Lippincott Williams & Wilkins: Philadelphia, 2006, pp 1401-1586.
5. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009; 69: 82-91.
6. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008; 8: 213-220.
7. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 2006; 99: 177-184.
8. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006; 44: 1465-1477.
9. Sidorenko SP, Clark EA. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 1993; 151: 4614-4624.
10. Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995; 376: 260-263.
11. Tatsuo H, Ono N, Tanaka K, Yanagi YSLAM. (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893-897.
12. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295-305.
13. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9: 431-455.
14. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, Tsao MS et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 2011; 7: e1002240.
15. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011; 480: 530-533.
16. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem 2001; 276: 43205-43215.
17. Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, Oezguen N et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008; 118: 2448-2458.
18. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69: 6694-6703.
19. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010; 134: 835-845.
20. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007; 7: 73.
21. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 2004; 78: 302-313.
22. Kobune F, Takahashi H, Terao K, Ohkawa T, Ami Y, Suzaki Y et al. Nonhuman primate models of measles. Lab Anim Sci 1996; 46: 315-320.
23. Terao-Muto Y, Yoneda M, Seki T, Watanabe A, Tsukiyama-Kohara K, Fujita K et al. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAMnegative cell lines. Antiviral Res 2008; 80: 370-376.
24. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006; 66: 11840-11850.
25. Inoue Y, Masutani Y, Kiryu S, Haishi T, Watanabe M, Tojo A et al. Integrated imaging approach to tumor model mice using bioluminescence imaging and magnetic resonance imaging. Mol Imaging 2010; 9: 163-172.
26. Sato H, Kobune F, Ami Y, Yoneda M, Kai C. Immune responses against measles virus in cynomolgus monkeys. Comp Immunol Microbiol Infect Dis 2008; 31: 25-35.
27. Takeda M, Takeuchi K, Miyajima N, Kobune F, Ami Y, Nagata N et al. Recovery of pathogenic measles virus from cloned cDNA. J Virol 2000; 74: 6643-6647.
28. El Mubarak HS, Yuksel S, van Amerongen G, Mulder PG, Mukhtar MM, Osterhaus AD et al. Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses. J Gen Virol 2007; 88: 2028-2034.
29. Zhu YD, Heath J, Collins J, Greene T, Antipa L, Rota P et al. Experimental measles. II. Infection and immunity in the rhesus macaque. Virology 1997; 233: 85-92.
30. Yanagi Y, Takeda M, Ohno S, Seki F. Measles virus receptors and tropism. Jpn J Infect Dis 2006; 59: 1-5.
31. de Swart RL, Ludlow M, de Witte L, Yanagi Y, van Amerongen G, McQuaid S et al. Predominant infection of CD150 lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 2007; 3: e178.
32. Leonard VH, Hodge G, Reyes-Del Valle J, McChesney MB, Cattaneo R. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol 2010; 84: 3413-3420.
33. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36: 929-939.
34. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919-4926.
35. Liszewski MK, Atkinson JP. Membrane cofactor protein. Curr Top Microbiol Immunol 1992; 178: 45-60.
36. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011; 49: 26-33.
37. Naniche D, Yeh A, Eto D, Manchester M, Friedman RM, Oldstone MB. Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production. J Virol 2000; 74: 7478-7484.
38. Ohno S, Ono N, Takeda M, Takeuchi K, Yanagi Y. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J Gen Virol 2004; 85: 2991-2999.
39. Takeda M, Ohno S, Tahara M, Takeuchi H, Shirogane Y, Ohmura H et al. Measles viruses possessing the polymerase protein genes of the Edmonston vaccine strain exhibit attenuated gene expression and growth in cultured cells and SLAM knockin mice. J Virol 2008; 82: 11979-11984.
40. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97: 3746-3754.
41. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009; 17: 1667-1676.
42. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009; 15: 7246-7255.
43. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010; 18: 1155-1164.
44. Tahara M, Takeda M, Shirogane Y, Hashiguchi T, Ohno S, Yanagi Y. Measles virus infects both polarized epithelial and immune cells by using distinctive receptorbinding sites on its hemagglutinin. J Virol 2008; 82: 4630-4637.
45. Watanabe A, Yoneda M, Ikeda F, Terao-Muto Y, Sato H, Kai C. CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J Virol 2010; 84: 4183-4193.
46. Kobune F, Sakata H, Sugiyama M, Sugiura A. B95a, a marmoset lymphoblastoid cell line, as a sensitive host for rinderpest virus. J Gen Virol 1991; 72(Pt 3): 687-692.
47. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14: 5773-5784.
48. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27: 493-497.
49. Masuda M, Sato H, Kamata H, Katsuo T, Takenaka A, Miura R et al. Characterization of monoclonal antibodies directed against the canine distemper virus nucleocapsid protein. Comp Immunol Microbiol Infect Dis 2006; 29: 157-165.
50. Iwata K, Seya T, Yanagi Y, Pesando JM, Johnson PM, Okabe M et al. Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46. J Biol Chem 1995; 270: 15148-15152.
51. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
52. Inoue Y, Kiryu S, Izawa K, Watanabe M, Tojo A, Ohtomo K. Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging. Eur J Nucl Med Mol Imaging 2009; 36: 771-779.